Allen C. Gao

University of California, Davis
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Year:

2026

Year:

2026

Year:

2025

Background: Treatment with androgen receptor (AR) signaling inhibitors, such as enzalutamide, can induce neural lineage plasticity in prostate cancer, potentially progressing to t-NEPC. However, the molecular mechanisms underlying this enzalutamide-driven plasticity, particularly the contribution of immune signaling pathways, remain poorly understood. Methods: We analyzed transcriptomic profiles of patient samples and prostate cancer cell lines to investigate changes in immune signaling pathways. Interferon gamma (IFNγ), interferon alpha (IFNα), and interleukin 6 (IL6)-Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) signaling were assessed in enzalutamide-sensitive and -resistant prostate cancer cells. Functional assays were conducted to examine cell responsiveness to cytokine stimulation and susceptibility to STAT1 inhibition using fludarabine. Results: Immune-related pathways, including IFNγ, IFNα, IL6-JAK-STAT3, and inflammatory responses, were significantly suppressed in NEPC patient samples compared to those with castration-resistant prostate cancer (CRPC). Enzalutamide-resistant and NEPC cells exhibited markedly impaired IFNγ and IL6 signaling. In contrast, early-stage enzalutamide treatment paradoxically enhanced IFNγ and IL6 responsiveness. Transcriptomic profiling revealed coordinated upregulation of E2F target genes and activation of IFNα/IFNγ and JAK/STAT signaling pathways during early treatment. Importantly, these early-stage cells remained highly sensitive to IFNγ and IL6 stimulation and showed increased susceptibility to STAT1 inhibition by fludarabine, a sensitivity that was lost in resistant cells. Conclusions: Early enzalutamide treatment enhances immune responsiveness, while the development of resistance is associated with suppressed immune signaling and increased lineage plasticity. These results suggest a therapeutic window where combining enzalutamide with STAT inhibitors may delay or prevent lineage plasticity and resistance.

Year:

2025

Background/Objective: The expression of human steroid sulfatase (STS) is upregulated in castration-resistant prostate cancer (CRPC) and is associated with resistance to anti-androgen drugs, such as enzalutamide (Enza) and abiraterone (Abi). Despite the known link between STS overexpression and therapeutic unresponsiveness, the mechanism by which STS confers this phenotype remains incompletely understood. In this study, we sought to understand how STS induces treatment resistance in advanced prostate cancer (PCa) cells by exploring its role in altering mitochondrial activity. Methods: To examine the effects of increased STS expression on mitochondrial respiration and programming, we performed RNA sequencing (RNA-seq) analysis, the Seahorse XF Mito Stress Test, and a mitochondrial Complex I enzyme activity assay in STS-overexpressing cells (C4-2B STS) and in enzalutamide-resistant CPRC cells (C4-2B MDVR). We employed SI-2, the specific chemical inhibitor of STS, on C4-2B STS and C4-2B MDVR cells and evaluated STS activity inhibition on mitochondrial molecular pathways and mitochondrial respiration. Lastly, we examined the effects of dehydroepiandrosterone sulfate (DHEAS) supplementation on C4-2B STS organoids. Results: We present evidence from the transcriptomic profiling of C4-2B STS cells that there are enriched metabolic pathway signatures involved in oxidative phosphorylation, the electron transport chain, and mitochondrial organization. Moreover, upon STS inhibition, signaling in the electron transport chain and mitochondrial organization pathways is markedly attenuated. Findings from the Seahorse XF Mito Stress Test and mitochondrial Complex I enzyme activity assay demonstrate that STS overexpression increases mitochondrial respiration, whereas the inhibition of STS by SI-2 significantly reduces the oxygen consumption rate (OCR) and Complex I enzyme activity in C4-2B STS cells. Similarly, an increased OCR and electron transport chain Complex I enzymatic activity are observed in C4-2B MDVR cells and a decreased OCR upon SI-2 inhibition. Lastly, we show that STS overexpression promotes organoid growth upon DHEAS treatment. Conclusions: Our study demonstrates STS as a key driver of metabolic reprogramming and flexibility in advanced prostate cancer. Disrupting enhanced mitochondrial respiration via STS presents a promising strategy in improving CRPC treatment.

Year:

2025

PINK1 expression is increased in 2B-OlapR cells and associated with negative patient prognosis. Treating 2B-OlapR cells with siPINK1 ASOs decreases PINK1 expression and protein level, as well as cell growth, and improves olaparib efficacy. A, Transcriptomic data reveal increased expression of PINK1 in the 2b-OlapR subline. B, qRT-PCR verification of increased PINK1 gene expression in 2b-OlapR cells. C, Western immunoblot analysis showing increased cellular PINK1 protein in 2b-OlapR cells. D, Deceased patients with prostate cancer have higher amounts of tumor PINK1 expression (Abida 2019). E, High-PINK1–expressing striated patients with prostate cancer show lower survival over time (GSE21032). F, 2B-OlapR cells treated with siPINK1 show lower mRNA expression through qRT-PCR (left) and decrease in cellular protein (right). G, siPINK1 treatment decreases growth of 2B-OlapR cells and increases relative olaparib efficacy at 5 μmol/L. * , P ≤ 0 . 05 ; * * , P ≤ 0 . 01 ; * * * , P ≤ 0 . 001 ; * * * * , P ≤ 0 . 0001 .

Year:

2025

Seahorse Mito Stress Test assay results comparing C4-2B and 2B-OlapR cells at basal state and with mitochondrial inhibitor supplementation to deduce relative function. A and B, Mito Stress Test summary graphic representing differential OCR and extracellular acidification rate between naïve and resistant cell lines under normal conditions and with the addition of mitochondrial inhibitors. C, Cellular OCR at basal state is increased in the olaparib-resistant cell line. D, Amount of oxygen consumption utilized for ATP production, derived through OCR difference before and after oligomycin (ETC complex V inhibitor) is added. 2B-OlapR displays increased oxygen consumption related to ATP production. E, Change in the OCR between basal readings and maximal readings after FCCP (mitochondrial membrane uncoupler) is added. 2B-OlapR cells exhibit greater ability to increase respiration under mitochondrial insult. F, Difference in cellular OCR reading after rotenone and antimycin A (complex I and III inhibitors) are added, eliminating all ETC-based oxygen consumption. 2B-OlapR cells show amplified maximal respiration compared with parental C4-2B. G, Difference between readings after oligomycin addition and the readings after antimycin A/rotenone addition, inferring oxygen consumption not ultimately utilized for ATP production. The rate in 2B-OlapR cells is almost twice that in C4-2B. ECAR, extracellular acidification rate. * * , P ≤ 0 . 01 ; * * * , P ≤ 0 . 001 ; * * * * , P ≤ 0 . 0001 .

Year:

2025

Inhibiting PINK1 expression decreases relative active mitochondria and lowers ETCC1 activity. A, Left, 2B-OlapR cells treated with siPINK1 show lower relative positive MitoTracker staining. 10× images shown, with 20× crops within. Right, MitoTracker to DAPI TCF ratio is reduced in the siPINK1 group. B, Left, Decreased PINK1 expression results in lower ETCC1 activity. Right, siPINK1-dosed 2B-OlapR cells report decreased the ETCC1 activity rate. * * , P ≤ 0 . 01 ; * * * * , P ≤ 0 . 0001 .

Year:

2025

Mitochondrial live stain and ETC functional test demonstrate higher function in 2B-OlapR cells. A, Left, MitoTracker staining counterstained with nuclear-specific DAPI reveals higher amounts of relative mitochondrial mass in 2B-OlapR cells over C42B. 10× images shown, with 20× crops within. Right, TCF ratio of MitoTracker to DAPI displaying quantification of relative increased active mitochondria in the resistant cell subline. B, Left, ETCC1 kit assay results express a higher rate of ETCC1 activity in 2B-OlapR cells. Right, Reported rate of change in NAD+ associated absorbance between 300 and 2,000 seconds show significant increased ETCC1 rate in 2B-OlapR cells. * * * , P ≤ 0 . 001 ; * * * * , P ≤ 0 . 0001 .

Year:

2024

Seahorse Mito Stress Test assay results comparing 2B-OlapR cells with and without siPINK treatment at basal state and with mitochondrially relevant pharmacologic supplementation to deduce relative function convey decreased function after PINK1 expression ablation. A and B, Mito Stress Test summary graphic representing differential OCR and extracellular acidification rate between nonspecific and siPINK1-targeted OlapR cells. C, Cellular OCR at basal state is greatly reduced with PINK1 excision. D, ATP production–associated oxygen consumption is markedly reduced in 2B-OlapR cells treated with siPINK1. E and F, PINK1 expression reduction reveals consequential decreased spare capacity for respiration, as well as lessened maximal rate of ETC-based oxygen consumption. G, Decreasing PINK1 levels leads to less proton leakage out of the inter-mitochondrial membrane space inferred by OCR reading differences after oligomycin addition and after rotenone and antimycin addition. ECAR, extracellular acidification rate. * * , P ≤ 0 . 01 ; * * * , P ≤ 0 . 001 .

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (13)

Aiming Yu

Professor

University of California, Davis

UNITED STATES
View details

Haojie Huang

Professor

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Shabber Mohammed

Researcher/Scientist III

Ohio State University

UNITED STATES
View details

Marc Dall'Era

Professor and Chair

university of california davis medical center

UNITED STATES
View details

Nicholas Mitsiades

Professor

University of California, Davis

UNITED STATES
View details

Eva Corey

Professor

University of Washington

UNITED STATES
View details

Jason E. Gestwicki

Professor

University of California, San Francisco

UNITED STATES
View details

Donald J Vander Griend

Professor

University of Illinois Chicago (UIC)

UNITED STATES
View details

Chengfei Liu

Associate Professor

UC Davis Health System

UNITED STATES
View details

Andrew JW Huang

Professor

Washington University in St. Louis

UNITED STATES
View details

Xiaolin Cheng

Associate Professor

Ohio State University

UNITED STATES
View details

Gagan Deep

Wake Forest School of Medicine

UNITED STATES
View details

Alan Lombard

Assistant Professor

University of California, Davis

UNITED STATES
View details